About: KP1019

An Entity of Type: chemical substance, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org:8891

KP1019, or indazole trans-[tetrachlorobis(1H-indazole)ruthenate(III)], is one of four ruthenium anti-cancer drugs to enter into phase I clinical trials, the others being BOLD-100, NAMI-A and TLD-1433. Research into ruthenium-based drugs has provided novel alternatives for platinum-based chemotherapeutics such as Cisplatin and its derivatives. KP1019 is useful for metastatic tumors and cis-platin resistant tumors. It exhibits potent cytotoxicity against primary tumors, particularly in colorectal cancer.

Property	Value
dbo:abstract	KP1019, or indazole trans-[tetrachlorobis(1H-indazole)ruthenate(III)], is one of four ruthenium anti-cancer drugs to enter into phase I clinical trials, the others being BOLD-100, NAMI-A and TLD-1433. Research into ruthenium-based drugs has provided novel alternatives for platinum-based chemotherapeutics such as Cisplatin and its derivatives. KP1019 is useful for metastatic tumors and cis-platin resistant tumors. It exhibits potent cytotoxicity against primary tumors, particularly in colorectal cancer. (en)
dbo:chEBI	77760
dbo:fdaUniiCode	DIO8FKP4J2
dbo:thumbnail	wiki-commons:Special:FilePath/Transferrin.2HAU.jpg?width=300
dbo:wikiPageID	50234622 (xsd:integer)
dbo:wikiPageLength	10874 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID	1108828410 (xsd:integer)
dbo:wikiPageWikiLink	dbc:Chloro_complexes dbc:Ruthenium_complexes dbr:NAMI-A dbc:Experimental_cancer_drugs dbc:Indazoles dbr:HT29 dbr:BOLD-100 dbc:Ruthenium(IV)_compounds dbr:File:HSA.1AO6.jpg dbr:File:Transferrin.2HAU.jpg dbr:SW480
dbp:c	21 (xsd:integer)
dbp:caption	KP1019 Chemical Structure (en)
dbp:chebi	77760 (xsd:integer)
dbp:cl	4 (xsd:integer)
dbp:h	19 (xsd:integer)
dbp:iupacName	trans-[Tetrachlorobisruthenate] (en)
dbp:n	6 (xsd:integer)
dbp:routesOfAdministration	Intravenous (en)
dbp:ru	1 (xsd:integer)
dbp:unii	DIO8FKP4J2 (en)
dbp:wikiPageUsesTemplate	dbt:Drugbox dbt:Reflist dbt:Cascite dbt:Fdacite
dcterms:subject	dbc:Chloro_complexes dbc:Ruthenium_complexes dbc:Experimental_cancer_drugs dbc:Indazoles dbc:Ruthenium(IV)_compounds
rdf:type	owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:Drug
rdfs:comment	KP1019, or indazole trans-[tetrachlorobis(1H-indazole)ruthenate(III)], is one of four ruthenium anti-cancer drugs to enter into phase I clinical trials, the others being BOLD-100, NAMI-A and TLD-1433. Research into ruthenium-based drugs has provided novel alternatives for platinum-based chemotherapeutics such as Cisplatin and its derivatives. KP1019 is useful for metastatic tumors and cis-platin resistant tumors. It exhibits potent cytotoxicity against primary tumors, particularly in colorectal cancer. (en)
rdfs:label	KP1019 (en)
owl:sameAs	yago-res:KP1019 wikidata:KP1019 https://global.dbpedia.org/id/2P9cZ dbr:KP1019
prov:wasDerivedFrom	wikipedia-en:KP1019?oldid=1108828410&ns=0
foaf:depiction	wiki-commons:Special:FilePath/HSA.1AO6.jpg wiki-commons:Special:FilePath/Transferrin.2HAU.jpg
foaf:isPrimaryTopicOf	wikipedia-en:KP1019
is dbo:wikiPageWikiLink of	dbr:RAPTA dbr:NAMI-A dbr:Bernhard_Keppler dbr:Ruthenium_anti-cancer_drugs dbr:BOLD-100
is foaf:primaryTopic of	wikipedia-en:KP1019